CN106459137B - 用于治疗眼部病症的膜附着性自组装体系 - Google Patents

用于治疗眼部病症的膜附着性自组装体系 Download PDF

Info

Publication number
CN106459137B
CN106459137B CN201580019868.9A CN201580019868A CN106459137B CN 106459137 B CN106459137 B CN 106459137B CN 201580019868 A CN201580019868 A CN 201580019868A CN 106459137 B CN106459137 B CN 106459137B
Authority
CN
China
Prior art keywords
phase
drug delivery
liquid crystal
delivery system
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580019868.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459137A (zh
Inventor
希哈·P·巴曼
里特什·V·塞克科达斯
凯文·L·沃德
安妮·玛丽·克罗姆维克
考希克·巴曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integral Biosystems LLC
Original Assignee
Integral Biosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems LLC filed Critical Integral Biosystems LLC
Publication of CN106459137A publication Critical patent/CN106459137A/zh
Application granted granted Critical
Publication of CN106459137B publication Critical patent/CN106459137B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
CN201580019868.9A 2014-05-01 2015-05-01 用于治疗眼部病症的膜附着性自组装体系 Active CN106459137B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987012P 2014-05-01 2014-05-01
US61/987,012 2014-05-01
PCT/US2015/028748 WO2015168523A1 (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Publications (2)

Publication Number Publication Date
CN106459137A CN106459137A (zh) 2017-02-22
CN106459137B true CN106459137B (zh) 2019-04-12

Family

ID=54359368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580019868.9A Active CN106459137B (zh) 2014-05-01 2015-05-01 用于治疗眼部病症的膜附着性自组装体系

Country Status (12)

Country Link
US (2) US9901544B2 (cg-RX-API-DMAC7.html)
EP (1) EP3137481B1 (cg-RX-API-DMAC7.html)
JP (1) JP6452725B2 (cg-RX-API-DMAC7.html)
KR (1) KR101890503B1 (cg-RX-API-DMAC7.html)
CN (1) CN106459137B (cg-RX-API-DMAC7.html)
AU (2) AU2015252908B2 (cg-RX-API-DMAC7.html)
CA (1) CA2946373C (cg-RX-API-DMAC7.html)
ES (1) ES2924768T3 (cg-RX-API-DMAC7.html)
MY (1) MY193694A (cg-RX-API-DMAC7.html)
NZ (1) NZ725028A (cg-RX-API-DMAC7.html)
SG (1) SG11201608729RA (cg-RX-API-DMAC7.html)
WO (1) WO2015168523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266446B1 (en) * 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
JPWO2018230713A1 (ja) * 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3643297A4 (en) * 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR THE TREATMENT OF GLAUCOMA
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
WO2019043169A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
JP7056480B2 (ja) * 2017-09-08 2022-04-19 ライオン株式会社 眼科用組成物及び涙液油層安定化剤
CN109316440B (zh) * 2018-09-29 2020-12-29 华中科技大学 一种温敏性液晶纳米水凝胶及其制备方法与应用
DK3870226T3 (da) * 2018-10-24 2023-09-18 Ferring Bv Mukoadhæsive farmaceutiske sammensætninger af kortikosteroider
GB201818043D0 (en) * 2018-11-05 2018-12-19 Waterford Institute Of Tech Artifical Tears
WO2021234548A1 (en) * 2020-05-18 2021-11-25 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
US11382910B2 (en) * 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
AU2021360121A1 (en) * 2020-10-13 2023-06-22 University Of South Australia Antimicrobial compositions and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20050235740A1 (en) * 2004-04-27 2005-10-27 Guido Desie Method to improve the quality of dispersion formulations
WO2008005819A2 (en) * 2006-06-30 2008-01-10 Cydex Pharmaceuticals, Inc. Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2013052647A2 (en) * 2011-10-04 2013-04-11 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
WO2013169647A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20130303502A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
JP4049216B2 (ja) * 2003-05-09 2008-02-20 ポーラ化成工業株式会社 液晶構造を有する製剤
CN101005828B (zh) * 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2008011836A2 (es) * 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
JP2010064995A (ja) * 2008-09-12 2010-03-25 Nikko Chemical Co Ltd 外用消炎鎮痛剤組成物
EP2518040B1 (en) * 2009-12-25 2018-10-31 Farnex Incorporated Low-viscosity liquid-crystal compound
CN101773670A (zh) * 2009-12-29 2010-07-14 中山大学 一种液晶药物载体
JP2012017318A (ja) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd 液晶及びそれを含有する皮膚外用剤
NZ728721A (en) * 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20050235740A1 (en) * 2004-04-27 2005-10-27 Guido Desie Method to improve the quality of dispersion formulations
WO2008005819A2 (en) * 2006-06-30 2008-01-10 Cydex Pharmaceuticals, Inc. Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2013052647A2 (en) * 2011-10-04 2013-04-11 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
WO2013169647A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20130303502A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof

Also Published As

Publication number Publication date
CA2946373A1 (en) 2015-11-05
JP6452725B2 (ja) 2019-01-16
AU2015252908A1 (en) 2016-10-27
AU2018201596A1 (en) 2018-03-29
MY193694A (en) 2022-10-25
US10603273B2 (en) 2020-03-31
US20180185275A1 (en) 2018-07-05
JP2017514843A (ja) 2017-06-08
US20170049697A1 (en) 2017-02-23
KR20160147784A (ko) 2016-12-23
AU2015252908B2 (en) 2017-12-07
ES2924768T3 (es) 2022-10-10
US9901544B2 (en) 2018-02-27
EP3137481B1 (en) 2022-07-06
WO2015168523A1 (en) 2015-11-05
CA2946373C (en) 2018-07-31
KR101890503B1 (ko) 2018-08-21
CN106459137A (zh) 2017-02-22
EP3137481A1 (en) 2017-03-08
EP3137481A4 (en) 2017-12-27
AU2018201596B2 (en) 2020-02-06
NZ725028A (en) 2019-01-25
SG11201608729RA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
CN106459137B (zh) 用于治疗眼部病症的膜附着性自组装体系
Gawin-Mikołajewicz et al. Ophthalmic nanoemulsions: From composition to technological processes and quality control
Ammar et al. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride
EP2978409B1 (en) Ophthalmic composition, method for preparing the same, and use of the same
Youshia et al. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide
TW201703770A (zh) 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
WO2020103958A1 (zh) 纳米晶滴眼剂、其制备方法及其应用
CN112135603A (zh) 包含奈必洛尔的药物组合物
Uner et al. Loteprednol loaded nanoformulations for corneal delivery: Ex-vivo permeation study, ocular safety assessment and stability studies
Nasser et al. Design, preparation and in-vitro evaluation of novel ocular antifungal nanoemulsion using posaconazole as a model drug
Jacob et al. Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy—an overview on recent advances. Pharmaceutics 2022; 14 (3): 533
Jaber et al. Preparation and evaluation of ascorbyl glucoside and ascorbic acid solid in oil nanodispersions for corneal epithelial wound healing
TW202116326A (zh) 用於製備無菌眼用水性丙酸氟替卡松a型奈米晶體懸浮液之方法
KR20150000405A (ko) 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법
Gautam et al. Tear-Driven Phase Transition Microemulsion for Ocular Delivery of Dexamethasone in the Effective Treatment of Uveitis
ES3012007T3 (en) Lipid-based ophthalmic composition for the treatment of dry eye
CN108042486A (zh) 亲脂性物质的水溶液，特别是药物物质溶液
HK1234413A1 (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
HK1234413B (zh) 用於治療眼部病症的膜附著性自組裝體系
Masareddy et al. Development of Bimatoprost-Loaded Nano Spanlastic In-Situ Gel for Ophthalmic Drug Delivery: A Box-Behnken Optimization Approach with In Vitro and Ex Vivo Characterization
Amrutkar et al. Formulation development and characterization of flucinolone acetonide nanoemulsion for ocular drug delivery system
Baig¹ et al. innovations in ocular drug
CN119385918A (zh) 一种治疗眼部新生血管疾病的瑞戈非尼原位凝胶制剂
Mehta et al. Intravitreal Injection Drug Delivery for
BR112017025757B1 (pt) Formulações oftálmicas de inibidores da tirosina quinase e suas composições farmacêuticas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1234413

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant